Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.

导出 OA

翻译打印收藏纠错

作者： Pat,Whitworth ^[1] ; Peter,Beitsch ^[2] ; Angela,Mislowsky ^[3] ; James V,Pellicane ^[4] ; Charles,Nash ^[5] ; Mary,Murray ^[6] ; Laura A,Lee ^[7] ; Carrie L,Dul ^[8] ; Michael,Rotkis ^[9] ; Paul,Baron ^[10] ; Lisette,Stork-Sloots ^[11] ; Femke A,de Snoo ^[11] ; Jennifer,Beatty ^[12]

作者单位： Nashville Breast Center, Nashville, TN, USA. patwhitworth@gmail.com. ^[1] Dallas Surgical Group, Dallas, TX, USA. ^[2] Coastal Carolina Breast Center, Murrells Inlet, SC, USA. ^[3] Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA, USA. ^[4] Northeast Georgia Medical Center, Gainesville, GA, USA. ^[5] Akron General Hospital, Akron, OH, USA. ^[6] Comprehensive Cancer Center, Palm Springs, CA, USA. ^[7] St. John Region, Grosse Pointe Woods, MI, USA. ^[8] Northern Indiana Cancer Research Consortium, South Bend, IN, USA. ^[9] Breast and Melanoma Specialists of Charleston, Charleston, SC, USA. ^[10] Department of Medical Affairs, Agendia Inc, Irvine, CA, USA. ^[11] The Breast Place, Charleston, SC, USA. ^[12]